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Vaccinia virus, a large double-stranded DNA virus, is the prototype of the Orthopoxvirus genus, which
includes several pathogenic poxviruses of humans, such as monkeypox virus and variola virus. Here,
we report a comprehensive yeast two-hybrid (Y2H) screening for the protein-protein interactions
between vaccinia and human proteins. A total of 109 novel vaccinia-human protein interactions were
detected among 33 viral proteins. To validate subsets of those interactions, we constructed an ORFeome
library of vaccinia virus strain WR using the Gateway plasmid cloning system. By co-expressing selected
vaccinia and host proteins in a variety of expression systems, we found that at least 17 of the Y2H hits
identiﬁed between vaccinia and human proteins can be veriﬁed by independent methods using GST
pull-down assays, representing a 63% validation rate for the Y2H hits examined (17/27). Because the
cloned ORFs are conveniently transferable from the entry vectors to various destination expression
vectors, the vaccinia ORFeome library will be a useful resource for future high-throughput functional
proteomic experiments.
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Introduction
In the postgenomic era, DNA sequencing databases are expo-
nentially accumulating and providing a vast opportunity to
construct representative libraries of cloned open reading frames
(ORFs), or ‘ORFeomes’, to enable high-throughput ‘omics’ ap-
plications.
1 For larger genomes that comprise hundreds or
thousands of ORFs, it is time-consuming to construct the OR-
Feome library through the conventional cloning method using
restriction endonucleases. In contrast, the Gateway site-speciﬁc
recombinational cloning system is a powerful tool, and many
ORFeomes, including human,
2 Caenorhabditis elegans
3 and some
bacterial,
4,5 have been generated using this methodology.
Virus members from the Poxviridae family all possess a
genome of double-stranded DNA containing about 150-300
ORFs.
6 For example, Variola virus from the Orthopoxvirus genus
is a lethal human-speciﬁc pathogen that causes smallpox,
probably the most lethal viral pathogen of man in history.
Although smallpox was successfully eradicated as an extant
human disease by the worldwide vaccination campaigns over
30 years ago, the concern for variola virus as a potential
bioweapon, as well as the potential emergence of related viruses
such as monkeypox, has renewed interest in the fundamental
mechanisms of orthopoxvirus pathogenesis.
7,8 However, direct
studies of variola virus virulence in nonhuman primate models
are exceedingly difﬁcult,
9 and monkeypox pathogenesis studies
can be very laborious and expensive.
10 Nevertheless, current
proteomic technologies permit researchers to extract important
clues about virus-host interaction dynamics by examination
of the protein-protein interactions between a virus and its
host. Such studies begin with the complete genomic database
of the virus (e.g., variola virus) and its host (e.g., humans).
The number of completely sequenced poxvirus genomes
now stands at over 100 (http://www.poxvirus.org/viruses.asp).
Most high-throughput proteomic studies in the past have been
performed with vaccinia virus, the prototype orthopoxvirus, and
the vaccine strain used to eradicate smallpox. For example, 37
interactions between sets of vaccinia proteins have been
identiﬁed with yeast two-hybrid (Y2H) assays.
11 In the case of
the variola ORFs that are not represented in the vaccinia virus
genome, several unique Y2H interaction hits with human
proteins have been detected, and a subset of these (e.g., variola
G1R with human NFkB1 and Skp1) have been validated
recently.
12
In addition, in vivo expression of entire poxviral proteomes has
also been carried out and many vaccinia proteins have been
expressed in Escherichia coli or baculovirus vectors.
13 However,
a vaccinia entry ORFeome platform that is easily convertible to
different destination expression vectors has not been previously
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Published on Web 07/28/2009reported. Poxviruses replicate extensively in the host cytoplasm
and have multiple strategies to manipulate a wide spectrum of
host cell pathways throughout the life cycle of the virus from the
entry to the exit.
14 These targeted pathways include innate
signaling circuits such as apoptosis, antiviral responses, and the
ubiquitin system.
14-18 Elucidation of the pathogenic mechanisms
of poxviruses and speciﬁc host-pathogen interactions require
functional analysis of how elements from both viruses and
eukaryotic hosts intersect. Many groups have exploited Y2H
screening to identify novel interactions between viral proteins and
human proteins. However, most studies in the past usually focus
on one viral protein at a time.
19-21
Here, we report more than 100 novel interactions between
proteins encoded by vaccinia virus (WR strain) and humans,
as identiﬁed by directed Y2H screening. To assess how many
of these Y2H hits could be validated by another independent
technology, we have selected a subset of the vaccinia-human
partners and expressed the tagged proteins in bacteria, trans-
fected human cells, or in reticulocyte lysates. Then, GST-
pulldown assays were utilized to assess which binding partners
deﬁned by Y2H analysis could be validated by an alternative
technology. As part of this validation, we constructed a
composite vaccinia ORFeome library in Gateway entry plasmid
vectors and then cassetted the query viral ORFs into Gateway
expression vectors suitable for expression and GST-pulldowns.
This vaccinia entry library permits viral ORFs to be easily
shuttled into other destination expression vectors, and should
provide a useful platform for systematic analysis of the mo-
lecular mechanisms that enable vaccinia to replicate success-
fully within its eukaryotic host. The Y2H results provide key
insights for the potential functions of vaccinia proteins to
modulate host cells during infection. It will also contribute to
a better understanding of host interaction dynamics of related
orthopoxviruses such as monkeypox and smallpox. However,
before Y2H results can be exploited, it is important to validate
potential protein-protein hits in independent expression
systems, such as we describe in this report.
Materials and Methods
Reagents. The vaccinia WR genomic DNA was a kind gift of
the laboratory of Dr. Richard Condit. Host gene constructs are
from Harvard Institute of Proteomics (HIP) or Open Biosystems.
Mouse anti-HA, mouse anti-myc and rabbit anti-HA were
obtained from Roche, Invitrogen, and Neomarkers.
Primer Design. All of the vaccinia ORFs were cloned as open
cassettes, with the terminator codon removed so as to permit
expression of C-tagged viral proteins. The primers in ﬁrst round
PCR were designed in the following strategy. The attB1 plus
Kozak segment (5-AAAGCAGGCTCCACC-3) was added before
the start codon of each forward primer, followed by ORF-
speciﬁc bases (see below). The attB2 segment (5-ACAA-
GAAAGCTGGGTCCAA-3) was added at the 5′-end of each
reverse primer, which was complementary to the end of the
ORF, without the last nucleotide of the stop codon, as previ-
ously described. The size (typically 15-27 bases) of the forward
and reverse primer parts that were complementary to the ORF
were determined to give a similar annealing temperature during
the PCR, usually in the range of 60-70 °C. The primers used
in second round PCR were the universal primers GM82
(5′GGGGACCACTTTGTACAAGAAAGCTGG GTC) and GM81
(5′GGGGACAAGTTTGTACAAAAAAGCAGGCTCC). All primers
were obtained from Invitrogen.
PCR Ampliﬁcation of the ORFs. Each PCR reaction was
performed in a 50-µL volume, with 1 unit of Platinum HiFi
polymerase (Invitrogen), MgSO4 2 mM, dNTP mix (0.2 mM
each), forward and reverse primers (0.125 µM each), and
genomic DNA (75 ng). Thirty PCR cycles (94 °C for 45 s, 55 °C
for 1 min, and 68 °C for 1 min/kb) were preceded by heating
to 94 °C for 2 min, and were followed by 5-min incubation at
68 °C. Conﬁrmation and size of the PCR products was deter-
mined by agarose gel electrophoresis.
BP Cloning Reaction of the Ampliﬁed ORFs. The BP
reactions were performed in a ﬁnal volume of 5 µL containing
1 µL of unpuriﬁed PCR product, 75 ng of pDONR221 or
pDNOR222 plasmid (from Invitrogen), and 1 µL of BP clonase
enzyme. The BP reactions were incubated for2ha t2 5°C and
used directly for bacterial transformation.
Transformation. Individual bacterial transformations were
carried out using 20 µL of transformation-ready Mach One cells,
5 µL of the BP reaction products, and 200 µL of SOC medium.
After the transformation reaction, E. coli transformants were
transferred to LB plates containing 25 µg/mL kanamycin.
Test of the Entry Clones. To identify and conﬁrm ORF entry
clones, PCR was performed, followed by sequencing of the
plasmid. The PCR was performed as described above, except
that 1 µL of the plasmid preparation was used as template and
universal primers GM81 and GM82 were used. The M13F and
M13R primers were used for sequencing. For those ORFs longer
than 2 kb, one or more internal ORF-speciﬁc primers were used
for sequencing.
Yeast Two-Hybrid (Y2H) Screening. Y2H screening was
carried out at Myriad Genetics (Salt Lake City, UT), similar to
that described for the unique open reading frames from variola
virus.
12 In brief, all vaccinia ORFs were cloned into the DNA-
binding domain vector, pGBT.superB, creating an ORF for each
of the vaccinia virus genes fused to the C-terminus of the GAL4
DNA-binding domain (residues 1-147). Each of the bait
plasmids was introduced into Myriad’s ProNet yeast strain
PNY200 (MATR ura3-52 ade2-101 trp1-901 his3-∆200 leu2-3,112
gal4∆ gal80∆). Expression of individual vaccinia baits was not
conﬁrmed for all constructs, and thus some potential vaccinia-
human interactions may have been missed as false negatives.
The bait yeast cells were allowed to mate with Myriad’s ProNet
MATa yeast cells, BK100 (MATa ura3-52 trp1-901 his3-∆200
leu2-3,112 gal4∆ gal80∆ GAL2-ADE2 LYS2::GAL1-HIS3 met2::
GAL7-lacZ) containing four independent cDNA libraries (prey
libraries) prepared from human tissues, cancer cell lines, or a
collection of clones [human tongue/tonsil, human spleen, a
combination of breast tumor and prostate tumor cell lines, and
the NIH sponsored Mammalian Gene Collection (MGC, http://
mgc.nci.nih.gov), respectively], fused to the C-terminus of the
Gal4 activation domain (residues 768-881) of the activation
domain vector, pGAD.PN2. Each library was generated from
random primed, directionally cloned cDNA which was typically
composed of over 5 million independent clones with an average
fragment size of 600-900 base pairs. Yeast transformants
positive for prey-bait interaction were selected on SD-Ade/-
His/-Leu/-Trp plate, and plasmid DNA isolated from positive
clones was sequenced.
GST Pulldown Assay. Puriﬁcation of GST and GST fusion
proteins from bacteria has been previously described.
22 Protein
expression by TNT system follows the protocol recommended
by the supplier (Promega). For GST-pulldown assays, all
incubations were performed at 4 °Cf o r1hi nPBS. After the
incubations, glutathione-sepharose beads (Amersham Bio-
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incubation buffer and then analyzed by SDS-PAGE followed
by Western blotting using chemiluminescence (Millipore, Bil-
lerica, MA).
Results and Discussion
Genome-Wide Yeast Two-Hybrid Screen for the Protein-
Protein Interactions between Vaccinia Virus and Human
Proteins. Vaccinia virus replication clearly requires a complex
protein interaction network to be established between virus
and host. Identiﬁcation and characterization of these protein-
protein interactions should provide a wealth of novel insights
into the biology of poxviruses in general. To identify all possible
interactions occurring between vaccinia virus and human
proteins, a directed Y2H screening was carried out. These assays
were conducted using four independent cDNA libraries pre-
pared from various human tissues, cancer cell lines, or a
collection of clones (human tongue/tonsil, human spleen, a
combination of breast tumor and prostate tumor cell lines, and
the NIH sponsored Mammalian Gene Collection (MGC, http://
mgc.nci.nih.gov), respectively). Of the 284 vaccinia ORFs
examined for human binding partners by Y2H screening, 33
vaccinia proteins revealed 109 new interactions with known
human proteins (Figure 1). The detailed interaction data is
listed in Table S1 (and is replicated at www.poxvirus.org).
For the Y2H screening, each vaccinia ORF was baited as a
full-length protein, and only when it was too large to be
expressed (as judged by our experience), it was divided into
overlapping baits. There was no effort to remove membrane
anchored tails or any other domains. The vaccinia bait con-
structs were all veriﬁed by sequence analysis. Since the bait
protein expression was not tested in yeast, it is possible that
some subclasses of interacting partners were missed. Conse-
quently, the percentage of bait proteins that yielded no hits
because they were not expressed in yeast cannot be estimated.
Figure 1. Y2H interaction networks between vaccinia virus and
human proteins. The interactions between vaccinia and human
proteins are based on Y2H screening results described in Table
S1. Viral proteins are labeled by the red triangles. Human
proteins are labeled in elliptical cycles. The host proteins with
more than one viral binding partner are indicated in yellow. The
blue lines are validated interactions in this paper. The name of
vaccinia proteins are labeled in red with the numbers of binding
partners inside the bracket.
Figure 2. Representative results of ﬁrst-round PCR products and
protein expression in destination vectors. (A) Electrophoretic
analysis of PCR products. The ﬁrst-round PCR products were
analyzed on SYBR-stained gels. (B) Western analysis of viral
expression in pANT7_cGST by TNT System using an antibody
against GST. All GST-fusion proteins are expressed at the
appropriate molecular weight (shown by an arrow). (C) West-
ern analysis of viral expression in pANT7_n-HA by TNT System
using an antibody against HA. All HA-fusion proteins except
WR026 are expressed at the appropriate molecular mass
(shown by an arrow).
Table 1. Summary of Vaccinia ORFeom Entry Vector Library
ORF correct
1 A.A.
mutation
2 A.A. and
more
mutations
correct and
minimal
mutations
difﬁcult
to clone total
Number 202 41 16 259 7 266
percentage 75.9% 15.4% 6.0% 97.4% 2.6% 100%
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virtue of expressing nutritional markers, we can verify that the
selectable marker was expressed in each plasmid.
From these studies, 12% of Y2H-expressed vaccinia proteins
revealed novel host protein-protein interactions, in which the
signal/noise criteria for “hits” were deﬁned very stringently.
Among the viral proteins that exhibited human protein interac-
tions, four vaccinia proteins WR022 (COP-C6), WR029 (COP-
N2), WR064 (COP-E8), and WR084 (COP-G6) each exhibited
more than 10 hits. Thirty-nine human proteins were found as
the potential binding partners for one relatively unexplored
viral ORF, WR022 (COP-C6), which suggests that this protein
is unusually “sticky” or has particularly diverse functions in
infected cells. Our validation of at least some of these interac-
tions should provide unique clues to elucidate the role of
WR022 (COP-C6).
The Y2H screening using a bait construct for WR064 (COP-
E8) identiﬁed 27 candidate interacting human proteins. WR064
(COP-E8) was previously shown to be a membrane protein
found in the virion and it is required for the formation of
transcriptionally active virus cores.
23,24 Nineteen human pro-
teins associated with WR084 (COP-G6) in the Y2H screening.
WR084 (COP-G6) belongs to NlpC/P60 superfamily and is
proposed to be involved in multiple virus-host interactions.
25
Finally, we identiﬁed 18 novel candidate human proteins
interacting with WR029 (COP-N2). WR029 (COP-N2) is an
alpha-amanitin target but its biological function is not clear.
26
Of the remaining vaccinia proteins with human interacting
protein hits, 12 viral proteins exhibited 3-10 hits and 17 viral
proteins had 1-2 hits. Note that some well-characterized
vaccinia-host protein interactions were missing from the list.
The Y2H technology identiﬁes the protein-protein interactions
between fusion proteins, both of which need to be faithfully
expressed and capable of interaction in the yeast nucleus. Also,
some proteins require speciﬁc conformation or post-transla-
tional modiﬁcations as a prerequisite to interact with their
binding partners. These types of interactions would not be
detected by Y2H assay (“false negatives”).
Other reasons to explain why Y2H screening would fail to
identify a host interacting partner that has been identiﬁed by
other means. For example, mutations can occur during the ORF
cloning that can prevent or abolish the interaction between
two proteins. One such example is the interaction between the
human topoisomerase II and vaccinia WR176 (COP-A50), which
can be prevented by mutating C11-to-Y at the N-terminus of
the viral bait.
27 Second, the type of fusion construct used can
affect the correct folding of the hybrid proteins. As another
example of a likely false negative in this Y2H screen, the
interaction between vaccinia WR040 (COP-F1) and human Bak
has also been well-documented in vivo and the interaction was
conﬁrmed by co-immunoprecipitation.
28 In general, it was not
possible to estimate what fraction of the recorded hits were
“false positives”, nor how many vaccinia-human interactions
simply could not be reproduced by the Y2H technology itself.
Nevertheless, despite these caveats, the Y2H assay is a
versatile tool to detect potential virus-host protein interactions
in vivo in a proteome-wide fashion. Because proteins usually
assemble into complexes to perform different activities, valida-
tion and characterization of the interactions from this Y2H
screening will contribute to the elucidation of which interacting
partners will shed mechanist insights into poxvirus biology.
Construction of Vaccinia Virus ORFeome Library. A two-
step PCR method was used in the vaccinia ORFs cloning such
that the viral ORF is in the open conﬁguration. To do so, the
Table 2. Positive GST Pulldown Validation Results of Selective Y2H Hits
a
vaccinia WR protein
(Copenhagen nomeclature) vaccinia protein function human protein
WR001 (COP-C23)* Chemokine binding protein KRT4* (Keratin)
WR022 (COP-C6)*,# Unknown KRT4* (Keratin 4)
PDCD6IP2 (Programmed cell death 6 interacting
protein)
TNNI2* (Troponin I, skeletal, fast)
WR026 (COP-C2)* Kelch-like intracellular protein that
inﬂuences the host response to VACV
infection
CRYAB* (Crystallin alpha B)
WR029 (COP-N2)* Unknown KPNA2* (Karyopherin alpha 2)
PLSCR4* (Phospholipid scramblase 4)
VCPIP1* (Valosin containing protein (p97)/p47
complex)
WR064(COP-E8)*,2 Membrane protein may help wrap virosome;
associates with IV/IMV and cores; F10L
kinase substrate
CD2BP2* (CD2 antigen-binding protein 2)
CRYAB* (Crystallin alpha B)
KHDRBS1* (KH domain containing, RNA binding,
signal transduction associated 1)
KIF2C* (Kinesin family member 2C)
PDIA6* (Protein disulﬁde isomerase-associated 6)
TPD52* (Tumor protein D52)
WR150 (COP-A27)* IMV surface protein; roles in IMV-cell
attachment, fusion, and microtubule
transport
KRT4* (Keratin 4)
WR171 (COP-A45)* Inactive Cu-Zn superoxide dismutase-like in
virion
SMAD* [SMAD1 (MAD homologue 1)]
WR196 (COP-B14)* IκB kinase inhibitor CDR2* (Paraneoplastic cerebellar
degeneration-associated antigen)
a WR, Western Reserve strain; COP, Copenhagen strain. Methods to produce recombinant proteins: *in vitro transcription/translation (TNT);
2mammalian cell; #bacterial.
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fusions with C-terminal tags in subsequent destination expres-
sion vectors. Primers for the ﬁrst-round PCR were designed to
generate a Gateway-compatible attB1 (forward primer) or attB2
(reverse primer) recombination site ﬂanking the ampliﬁed ORF.
Full-length attB sites at the 5′ and 3′ends were generated using
universal adapter primers in the second round PCR. In cases
where the production of C-terminal fusion proteins is desired,
which can be expressed from appropriate destination vectors,
the stop codon of each ORF was removed in the reverse
primers.
Vaccinia virus WR strain contains 284 predicted ORFs, of
which 18 ORFs are duplicated within the terminal inverted
repeat sequences of the viral genome. All the unique 266 ORF
products could be ampliﬁed by PCR and were detected by SYBR
staining. Figure 2A is a representative electrophoretic analysis
of ﬁrst-round PCR products. Following second-round PCR with
universal primers, the products were ready for insertion into
the Gateway entry vectors.
The PCR products were next inserted into entry vectors like
pDONR222 or pDONR221 by BP Clonase recombination. The
products resulting from site-speciﬁc recombination were trans-
formed into transfection-sensitized One Shot Mach One bacte-
rial cells. A portion of the transformed cells was then plated
on solid medium containing Kanamycin. Colonies from each
plate were then tested in a colony-PCR with primer 81 and
primer 82. The resulting PCR products were detected by gel
electrophoresis and SYBR staining. Transformants that pro-
duced an insert of the expected size for the input ORF were
selected and grown in liquid medium containing Kanamycin
to generate bacterial glycerol stocks for long-term storage. By
this approach, we successfully obtained 259 transformants
Figure 3. Representative results of GST pulldown validation experiments. (A) WR022 (COP-C6) interacts with KRT4. WR022 (COP-C6)
expressed as a GST fusion protein from bacteria was bound to beads and incubated with KRT4 expressed by TNT System for a pulldown
experiment. KRT4 was detected by immunoblotting for HA, whereas GST proteins were detected by Coomassie staining. Star indicates
the position of full-length GST-WR022 (COP-C6). (B) WR026 (COP-C2) interacts with CRYAB. Cell lysates from pANT7_cGST-WR026
(COP-C2) and pCDNA-CRYAB co-transfected, or from pCDNA-CRYAB transfected BSR-T7 cells were bound to beads and incubated for
a pulldown experiment. CRYAB was detected by immunoblotting for myc, whereas GST proteins were detected by Coomassie staining.
Arrow indicates the position of full-length GST-WR026 (COP-C2). (C) WR064 (COP-E8) interacts with CRYAB and CD2BP2. (D) WR064
(COP-E8) interacts with PDIA6, KHDRBS1 and TPD52. To generate (C) and (D), proteins were co-expressed in the TNT system as follows:
plasmid pANT7_nHA-WR064, with pANT7_cGST-CRYAB, pANT7_cGST-CD2BP2, pANT7_cGST-KPNA2, pANT7_cGST-VCPIP1, pANT7_cGST-
PDIA6, pANT7_cGST-KHDRBS1 or pANT7_cGST-TPD52. KPNA2 and VCPIP1were used as negative controls. On the basis of the Y2H
screen, neither KPNA2 nor VCPIP1 interacts with WR064 (COP-E8). In addition, to our knowledge, there is not a report that suggests
that a pair of proteins used as controls are interacting partners. Once expressed, recombinant proteins were bound to glutathione-
sepharose beads for the pulldown experiment. WR064 (COP-E8) was detected by immunoblotting for HA, whereas GST fusion proteins
were detected by immunoblotting for GST.
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entry plasmid. The single-colony glycerol stocks and the
puriﬁed entry plasmid clones together constitute the composite
ORFeome library of Vaccinia virus WR strain.
To verify that the inserted vaccinia ORFs were in the correct
reading frame and indeed corresponded to the assigned
identity, all the plasmids were sequenced with an M13 forward
primer. For longer ORFs, M13 reverse primer or internal
primers were needed to verify the ORF sequence. The summary
of the vaccinia entry library is listed in Table 1. Our entry library
successfully covers 97.4% of the predicted vaccinia strain WR
ORFeome. A total of 202 vaccinia ORFs were found to be
correctly cassettted within the entry vector. Forty-one ORFs
contained a single amino acid (A.A.) change from the WR
sequence reported and 16 ORFs contained 2 A.A. or more
changes. Seven vaccinia ORFs (WR002, WR019, WR065, WR073,
WR098, WR110 and WR176) were difﬁcult to clone into entry
vectors and remain uncloned.
Expression of Recombinant Tagged Proteins from Differ-
ent Expression Vectors. Different entry clones were each
subjected to a recombination reaction, the LR-Reaction, which
recombines the attL-sites on the entry clones with the attR-
sites on the destination vectors. Entry vectors were shuttled
into the pANT7_nHA vector (HIP) designed to make a fusion
protein with an N-terminal HA-Tag, or with the pANT7_cGST
vector (HIP), creating fusion proteins with a C-terminal GST-
Tag. The resulting products were in vitro transcribed and
translated with the TNT Coupled Transcription/Translation
System from Promega and 2 µL of total products were analyzed
by Western blot with anti-HA or anti-GST antibodies. Protein
expression was detected for all GST-tagged vectors and most
of the HA-tagged vectors. Representative Western blot results
are shown in Figure 2B,C.
There are many valuable applications for the cloned vaccinia
ORFeome library. The validation of protein-protein interac-
tions detected from Y2H screening can be facilitated by
shuttling the candidate ORFs from entry vectors into various
expression vectors. For example, viral proteins with ﬂuorescent
protein tags can be generated to investigate viral proteins
localization. Further application of the vaccinia ORFeome will
be high-throughput recombinant proteins expression with
different tags in different expression systems. The vaccinia
ORFeome can also help construct DNA microarrays by ampli-
ﬁcation of the ORFs with a single pair of primers.
Validation the Protein-Protein Interactions in Vitro Us-
ing the Vaccinia Virus ORFeome. To validate the tentative
protein interaction hit results obtained from Y2H screening,
we primarily used pulldown assays using GST conjugated beads
to precipitate GST-tagged proteins, which are generated from
bacteria, transfected mammalian cells, or TNT in vitro expres-
sion system. The GST pulldown was followed by SDS-PAGE and
Western blot analysis to identify the viral or host-GST partner
that has a different epitope tag, such as -HA, or Myc-His.
A total of 27 tentative Y2H interactions were chosen for
validation, and of these, 17 proved to be positive by GST
pulldown, which represents 63% of the selected Y2H hits (Table
2). The two main criteria used to select the chosen 27 Y2H
interactions for validation were based on the following. First,
the cloned human cDNA were readily available in Gateway
vectors from HIP (Harvard Institute of Proteomics) or Open
Biosystems. Second, when the levels of protein expression were
determined following transfection into mammalian cells or in
reticulocyte lysates, and those clones that expressed well were
chosen for validation. Representative results of these validations
are shown in Figure 3. Some of the more intriguing vaccinia-
human protein interactions are discussed in detail below.
In the potential human binding partners identiﬁed in the
Y2H screening, KPNA2 is noteworthy because it interacts with
proteins from multiple pathogens, such as adenovirus, EBV,
HIV, Papillomavirus and Sarcoma virus.
29 KPNA2 plays a key
role in both the import and export of intracellular cargo across
the nuclear membrane. WR029 (COP-N2), a validated Y2H
partner for this cellular protein, is of unknown function, but it
localizes to the host cell nucleus during VV infection.
26 Interac-
tions between WR029 (COP-N2) and KPNA2 may provide clues
as to the function of this viral protein in the nucleus. Another
interesting result is the interaction between PLSC4 and WR029
(COP-N2). Phospholipid scramblases (PLSCRs) are a family of
proteins involved in destroying membrane phospholipid asym-
metry for diverse cellular events.
30 PLSCR4 is one of four
members known in humans. Although a nuclear localization
signal was identiﬁed in PLSCR4, a detailed mechanism of
PLSCR4 still awaits a proper investigation. Interaction of WR029
(COP-N2) with PLSCR4 suggested that this viral protein might
Table 3. Negative Validation Results of Selective Y2H Hits
a
vaccinia WR protein
(Copenhagen nomenclature) vaccinia protein function human protein
WR022 (COP-C6)*,# Unknown AP2B1* (Adaptor-related protein complex 2,
beta 1 subunit)
Exo72 (Exocyst complex component 7)
SLK* (STE20-like kinase)
WR029 (COP-N2)* Unknown KPNA5* (Karyopherin alpha 5)
PRDX4* (Peroxiredoxin 4)
WR034 (COP-K3)2 Interferon resistance and eIF2 alpha-like
PKR inhibitor
IL322 (Interleukin 32)
WR039 (COP-K7)*,# Suppressor of DDX3- mediated IRF
activation and INF  promoter induction
ARNTL* (Aryl hydrocarbon receptor nuclear
translocator-like)
WR064 (COP-E8)* Membrane protein may help wrap virosome;
associates with IV/IMV and cores; F10L
kinase substrate
CTNNB1* [Catenin (cadherin-associated
protein), beta 1]
WR150 (COP-A27)* IMV surface protein; roles in IMV-cell
attachment, fusion, and microtubule
transport
Unc84B* (Unc-84 homologue B)
BAP1* (BRCA1 associated protein 1)
a WR, Western Reserve strain; COP, Copenhagen strain. Methods to produce recombinant proteins: *in vitro transcription/translation (TNT);
2mammalian cell; #bacterial.
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Another WR029 (COP-N2) interaction partner, VCPIP1 (also
named VCIP135), was identiﬁed as an essential factor for p97/
p47-mediated membrane fusion, and dissociates it via p97
catalyzed ATP hydrolysis.
31 Reassembly of Golgi cisternae
mediated by p97-p47 during mitotic requires the deubiquiti-
nating activity of VCPIP1.
32 Future work needs to be done to
test whether WR029 (COP-N2) actually plays a role in this
process.
KRT4 was shown to interact with three different vaccinia
proteins: WR001 (COP-C23), WR022 (COP-C6) and WR150
(COP-A27). KRT4 is one type of intermediate ﬁlaments and the
interaction with IMV surface protein WR150 (COP-A27) may
take part in IMV-cell attachment, fusion, and/or microtubule
transport.
PDIA6 and CRYAB are human binding partners for WR064
(COP-E8). PDIA6 belongs to protein disulﬁde isomerase family,
while CRYAB, small heat shock protein, has been shown to
suppress the protein aggregation.
33 Considering WR064 (COP-
E8) is a transmembrane protein component of the vaccinia
virion, PDIA6 and CRYAB might facilitate proper protein folding
for this viral protein.
TNNI2 was one binding partner identiﬁed for WR022 (COP-
C6) in our validation. TNNI2 was suggested to be a novel co-
activator of ERRR.
34 It will be interesting to investigate if WR022
(COP-C6) has a role in ERRR-mediated transcriptional activity.
SMAD1 is a key molecule in TGF /BMP signaling pathway.
35
WR171 (COP-A45) is a viral core protein and has no known
role in virus replication or virulence.
36 The association of
SMAD1 with WR171 (COP-A45) suggested the possibility that
this vaccinia protein may be involved in TGF /BMP signaling
pathway.
Ten Y2H interactions from our validation selection turned
out to be negative by the GST-pulldown assay (Table 3).
However, based on our validation methodology, we still cannot
rule out the possibilities that such interactions do occur in
virus-infected cells in vivo. Different reasons can justify nega-
tive results. For example, the position of the epitope tags at
the N-terminus or C-terminus could be very critical in the sense
that it might negatively interfere with the interaction per se.
On the other hand, the TNT expression system used may not
be the most efﬁcient method to express certain viral or human
proteins. Consequently, the low levels of expression or high
levels of expression of particular partners can also lead to
apparent negative results.
Clearly, further work is needed to validate all the interactions
from the Y2H screen and understand their potential physi-
ological relevance during vaccinia virus infection.
Conclusion
We have identiﬁed over 100 protein-protein interactions
between vaccinia virus and human proteins by Y2H screening.
A signiﬁcant number of the vaccinia proteins identiﬁed in the
Y2H screen have been only partially characterized or not
characterized at all. The host binding partners, when validated,
will provide insightful clues for the function of those viral
proteins. As well, many of the deduced mechanisms of
vaccinia-host interactions can also apply to monkeypox and
variola virus. The generation of nearly complete vaccinia
ORFeome is an important step for introducing high-throughput
approaches to orthopoxvirus research.
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